VA
CBIO

VR Adviser’s Crescent Biopharma CBIO Stock Holding History

VR Adviser’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.2M Hold
2,133,576
– – 1.46% 19
2025
Q4 		$25.3M Buy
2,133,576
+745,712
+54% +$9.5M 1.25% 22
2025
Q3 		$16.5M Hold
1,387,864
– – 0.93% 26
2025
Q2 		$22.4M Buy
1,387,864
+1,357,864
+4,526% +$28.7M 1.68% 17
2025
Q1 		$630K Hold
30,000
– – 0.05% 36
2024
Q4 		$747K Buy
+30,000
New +$818K 0.05% 36

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

VR Adviser's CBIO Position: Q1 2026 in Review

VR Adviser held its Crescent Biopharma (CBIO) position steady in Q1 2026 at 2,133,576 shares worth $39.2M. The position accounts for 1.46% of the portfolio, ranked #19.

VR Adviser first reported a position in CBIO in Q4 2024 and has held it in 6 quarters since. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • VR Adviser held 2,133,576 shares of Crescent Biopharma worth $39.2M as of Q1 2026.
  • VR Adviser left its Crescent Biopharma share count unchanged in Q1 2026.
  • Crescent Biopharma made up 1.46% of VR Adviser's portfolio in Q1 2026, its #19 holding.
  • VR Adviser first reported a position in Crescent Biopharma in Q4 2024 and has held it in 6 quarters since.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.